CASI Pharmaceuticals Inc (NASDAQ:CASI) and BioInvent International AB announced preliminary efficacy data for BI-1206 in combination with rituximab in patients with relapsed/refractory (R/R) indolent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results